Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Prostatic Neoplasms 4Lung Neoplasms 3Urogenital Neoplasms 2Leukemia 2Stomach Neoplasms 1Solid Tumors 1Small Cell Lung Carcinoma 1Recurrence 1Recovery 1Ovarian Neoplasms 1Metabolic Diseases 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Keratosis, Actinic 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumors × Powders × Clear all
NCT01049893 2019-02-12

Dose Finding, Safety and Tolerability Study for AC220 to Treat Advanced Solid Tumors

Daiichi Sankyo

Phase 1 Completed
45 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡